Analysis Of Clinical Features Of Gene Mutation And In Acute Myeloid Leukemiapatients With AML1-ETO Fusion Gene

Objective:1.Objective to investigate the clinicalfeatures of acute myeloid leukemiapatients with AML1-ETO fusion gene.2.To analyze whether AML1-ETO-positive acute myeloid leukemia patients,when c-kit mutations appear,will cause this type of AML patients to show unique clinical characteristics and the relationship between c-kit mutations and prognosis;and explore the relationship between other gene mutations and the clinical parameters and prognosis of the patient.Methods:Choose 64 patients with AML1-ETO-positive acute myeloid leukemia who admitted to the Hematology Department of the First Affiliated Hospital of Bengbu Medical College from 2015.01 to 2019.09 and collected their clinical data.According to whether AML1-ETO-positive AML patients had c-kit mutations,they were divided into 2groups:(1)c-kit mutation group;(2)non-c-kit mutation group.Comparedthe difference of clinical characteristics and laboratory data between the two groups of patients.In order to exclude other poor-prognosis gene mutations or poor-prognosis mutations reported in the literature affecting research,patients with non-c-kit mutation groups with FLT3,WT1,and TET2 mutations were further classified as poor mutation groups;Analysze correlation between c-kit mutation and eachclinical parameters and further analyze whether there is a difference in prognosis between the c-kit mutant group and each subgroup.Results:1.Compared with the non-c-kit mutation group,it could be found that the c-kit mutation group had an increase in WBC levels,a decrease in PLT levels,and the difference was statistically significant(P <0.05).At the same time,the CD56 expression rate increasesd,and the survival time was shorter.There were statistically significant differences between the groups(P <0.05).There was no significant difference in recurrence rate and outcome between the two groups.2.Further subgroup analysis showed that compared with the bad mutation group,the WBC level in the c-kit mutation group was higher,and the difference was statistically significant(P <0.05).Compared with the simple AML1-ETO positive group,the level of PLT in the c-kit mutant group was lower,and the difference was statistically significant(P <0.05).Compared with the bad mutation group,the c-kit mutation group was more likely to express CD56,and the difference was statistically significant(P<0.05).3.In the survival time and relapse time,the survival time of patients in the c-kit mutation group and the bad mutation group were significantly shorter than those in the simple AML1-ETO positive group,and the results were statistically different(P <0.05);however,the mutation type had no effect on survival time and relapse time.Therecurrence rates of c-kit mutation group,simple AML1-ETO positive group,and bad mutation group were 25%,31.7%,and 45.5%,respectively,but there was no significant difference between the three groups.Similarly,the presence or absence of mutations had no effect on CR rate and survival outcomes(P> 0.05).4.Kaplan-Meier method was used to compare the survival of the three groups of patients,and the survival curve was drawn.The survival curve of the simple AML1-ETO positive group is above the other two groups.It could be seen that the prognosis of the c-kit mutation group and the bad mutation group is worse than that of the simple AML1-ETO positive group,but the difference between the c-kit mutation group and the bad mutation group hdh no statistical significance.Conclusions:1.c-kit mutations were closely related to AML1-ETO-positive AML patients.When c-kit mutations occured,WBC levelsincreased,PLT levels decreased,and relapse time was shortened in this type of AML patients.The increase in CD56 expression rate was related to c-kit mutations.To a certain extent,provided guidance for the diagnosis and treatment of AML1-ETO positive AML patients.2.The incidence of other poor prognostic mutations(WT1,FLT3,TET2,etc.)in is low,but it have a large impact on the survival time of AML1-ETO-positive AML patients.Therefore,it is necessary to expand the sample size to conduct in-depth research on these mutant genes.